Omacor in Prevention of Cardiovascular Events in Patients Undergoing Chronic Hemodialysis
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
The aim of this investigator initated study is to examine the effect of OMACOR (Omega-3-acid
ethyl ester 90) on the incidence of cardiovascular events and mortality in patients
undergoing chronic hemodialysis, who has previously experienced a cardiovascular event.
Phase:
Phase 4
Details
Lead Sponsor:
Pronova BioPharma
Collaborators:
Danish Heart Foundation North Jutland County The Danish Kidney Association